{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:34:36Z","timestamp":1790678076753,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40520-020-01777-9","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T09:03:26Z","timestamp":1610701406000},"page":"2529-2537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A novel effervescent formulation of oral weekly alendronate (70\u00a0mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8041-4566","authenticated-orcid":false,"given":"Andrea","family":"Giusti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerolamo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"1777_CR1","unstructured":"Kanis JA, on behalf of the WHO Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK"},{"key":"1777_CR2","doi-asserted-by":"publisher","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","volume":"2","author":"R Eastell","year":"2016","unstructured":"Eastell R, O\u2019Neill TW, Hofbauer LC et al (2016) Postmenopausal osteoporosis. Nat Rev Dis Primers 2:16069. https:\/\/doi.org\/10.1038\/nrdp.2016.69","journal-title":"Nat Rev Dis Primers"},{"key":"1777_CR3","first-page":"21","volume":"49","author":"A Caliri","year":"2007","unstructured":"Caliri A, De Filippis L, Bagnato GL et al (2007) Osteoporotic fractures: mortality and quality of life. Panminerva Med 49:21\u201327","journal-title":"Panminerva Med"},{"key":"1777_CR4","unstructured":"Overview | Bisphosphonates for treating osteoporosis | Guidance | NICE. https:\/\/www.nice.org.uk\/guidance\/ta464. Accessed 5 Feb 2020"},{"key":"1777_CR5","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM et al (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab 104:1595\u20131622. https:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"key":"1777_CR6","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118\u20134124. https:\/\/doi.org\/10.1210\/jcem.85.11.6953","journal-title":"J Clin Endocrinol Metab"},{"key":"1777_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1592\/phco.28.4.437","volume":"28","author":"BA Briesacher","year":"2008","unstructured":"Briesacher BA, Andrade SE, Fouayzi H et al (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28:437\u2013443. https:\/\/doi.org\/10.1592\/phco.28.4.437","journal-title":"Pharmacotherapy"},{"key":"1777_CR8","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","volume":"17","author":"D Weycker","year":"2006","unstructured":"Weycker D, Macarios D, Edelsberg J et al (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645\u20131652. https:\/\/doi.org\/10.1007\/s00198-006-0179-x","journal-title":"Osteoporos Int"},{"key":"1777_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40520-014-0256-5","volume":"27","author":"M Invernizzi","year":"2015","unstructured":"Invernizzi M, Cisari C, Carda S (2015) The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment. Aging Clin Exp Res 27:107\u2013113. https:\/\/doi.org\/10.1007\/s40520-014-0256-5","journal-title":"Aging Clin Exp Res"},{"key":"1777_CR10","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","volume":"21","author":"I Imaz","year":"2010","unstructured":"Imaz I, Zegarra P, Gonz\u00e1lez-Enr\u00edquez J et al (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943\u20131951. https:\/\/doi.org\/10.1007\/s00198-009-1134-4","journal-title":"Osteoporos Int"},{"key":"1777_CR11","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022. https:\/\/doi.org\/10.4065\/81.8.1013","journal-title":"Mayo Clin Proc"},{"key":"1777_CR12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","volume":"122","author":"ES Siris","year":"2009","unstructured":"Siris ES, Selby PL, Saag KG et al (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3-13. https:\/\/doi.org\/10.1016\/j.amjmed.2008.12.002","journal-title":"Am J Med"},{"key":"1777_CR13","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s00198-018-4630-6","volume":"29","author":"J Liu","year":"2018","unstructured":"Liu J, Guo H, Rai P et al (2018) Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis. Osteoporos Int 29:2409\u20132417. https:\/\/doi.org\/10.1007\/s00198-018-4630-6","journal-title":"Osteoporos Int"},{"key":"1777_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00965-9","author":"N Li","year":"2020","unstructured":"Li N, Cornelissen D, Silverman S et al (2020) An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics. https:\/\/doi.org\/10.1007\/s40273-020-00965-9","journal-title":"Pharmacoeconomics"},{"key":"1777_CR15","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00198-020-05378-0","volume":"31","author":"D Cornelissen","year":"2020","unstructured":"Cornelissen D, de Kunder S, Si L et al (2020) Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int 31:1645\u20131669. https:\/\/doi.org\/10.1007\/s00198-020-05378-0","journal-title":"Osteoporos Int"},{"key":"1777_CR16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","volume":"28","author":"A Diez-Perez","year":"2017","unstructured":"Diez-Perez A, Naylor KE, Abrahamsen B et al (2017) International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int 28:767\u2013774. https:\/\/doi.org\/10.1007\/s00198-017-3906-6","journal-title":"Osteoporos Int"},{"key":"1777_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster J-Y, Tosteson ANA et al (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int 30:45\u201357. https:\/\/doi.org\/10.1007\/s00198-018-4744-x","journal-title":"Osteoporos Int"},{"issue":"P40","key":"1777_CR18","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1002\/jbm4.10229","volume":"3","author":"B Cortet","year":"2019","unstructured":"Cortet B, Fardellone P, Zakin L et al (2019) Upper gastrointestinal safety with the buffered solution of alendronate 70 mg: 6 years of post-marketing experience. JBMR Plus 3(P40):S75. https:\/\/doi.org\/10.1002\/jbm4.10229","journal-title":"JBMR Plus"},{"key":"1777_CR19","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s40520-019-01205-7","volume":"31","author":"S Gonnelli","year":"2019","unstructured":"Gonnelli S, Caffarelli C, Letizia Mauro G et al (2019) Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study. Aging Clin Exp Res 31:1541\u20131547. https:\/\/doi.org\/10.1007\/s40520-019-01205-7","journal-title":"Aging Clin Exp Res"},{"key":"1777_CR20","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.3275\/7862","volume":"34","author":"M Pedrazzoni","year":"2011","unstructured":"Pedrazzoni M, Girasole G, Giusti A et al (2011) Assessment of the 10-year risk of fracture in Italian postmenopausal women using FRAX\u00ae: a north Italian multicenter study. J Endocrinol Invest 34:e386\u2013e391. https:\/\/doi.org\/10.3275\/7862","journal-title":"J Endocrinol Invest"},{"key":"1777_CR21","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00198-019-05104-5","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Cornelissen D, Vrijens B et al (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporos Int 30:2155\u20132165. https:\/\/doi.org\/10.1007\/s00198-019-05104-5","journal-title":"Osteoporos Int"},{"key":"1777_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH et al (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res 22:465\u2013475. https:\/\/doi.org\/10.1359\/jbmr.061113","journal-title":"J Bone Miner Res"},{"key":"1777_CR23","first-page":"1426","volume":"166","author":"AB Hodsman","year":"2002","unstructured":"Hodsman AB, Hanley DA, Josse R (2002) Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ 166:1426\u20131430","journal-title":"CMAJ"},{"key":"1777_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","volume":"48","author":"JS McCombs","year":"2004","unstructured":"McCombs JS, Thiebaud P, McLaughlin-Miley C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271\u2013287. https:\/\/doi.org\/10.1016\/j.maturitas.2004.02.005","journal-title":"Maturitas"},{"key":"1777_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00198-007-0466-1","volume":"19","author":"FJA Penning-van Beest","year":"2008","unstructured":"Penning-van Beest FJA, Erkens JA, Olson M et al (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511\u2013517. https:\/\/doi.org\/10.1007\/s00198-007-0466-1","journal-title":"Osteoporos Int"},{"key":"1777_CR26","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008. https:\/\/doi.org\/10.1007\/s00198-004-1652-z","journal-title":"Osteoporos Int"},{"key":"1777_CR27","first-page":"25","volume":"3","author":"A H\u00f6er","year":"2009","unstructured":"H\u00f6er A, Seidlitz C, Gothe H et al (2009) Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 3:25\u201330","journal-title":"Patient Prefer Adherence"},{"key":"1777_CR28","first-page":"123","volume":"11","author":"S Coaccioli","year":"2014","unstructured":"Coaccioli S, Celi G, Crapa ME et al (2014) Alendronate soluble solution: a higher adherence rate in the treatment of osteoporosis. Clin Cases Miner Bone Metab 11:123\u2013125","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"Suppl 1","key":"1777_CR29","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1007\/s40520-013-0127-5","volume":"25","author":"G Iolascon","year":"2013","unstructured":"Iolascon G, Gimigliano F, Orlando V et al (2013) Osteoporosis drugs in real-world clinical practice: an analysis of persistence. Aging Clin Exp Res 25(Suppl 1):S137-141. https:\/\/doi.org\/10.1007\/s40520-013-0127-5","journal-title":"Aging Clin Exp Res"},{"key":"1777_CR30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1185\/030079906X167615","volume":"23","author":"DT Gold","year":"2007","unstructured":"Gold DT, Martin BC, Frytak JR et al (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585\u2013594. https:\/\/doi.org\/10.1185\/030079906X167615","journal-title":"Curr Med Res Opin"},{"key":"1777_CR31","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s00198-006-0085-2","volume":"17","author":"JC Lo","year":"2006","unstructured":"Lo JC, Pressman AR, Omar MA et al (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922\u2013928. https:\/\/doi.org\/10.1007\/s00198-006-0085-2","journal-title":"Osteoporos Int"},{"key":"1777_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00198-007-0506-x","volume":"19","author":"V Rabenda","year":"2008","unstructured":"Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811\u2013818. https:\/\/doi.org\/10.1007\/s00198-007-0506-x","journal-title":"Osteoporos Int"},{"key":"1777_CR33","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2215\/CJN.04211007","volume":"3","author":"SC Cheng","year":"2008","unstructured":"Cheng SC, Young DO, Huang Y et al (2008) A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3:1131\u20131138. https:\/\/doi.org\/10.2215\/CJN.04211007","journal-title":"Clin J Am Soc Nephrol"},{"key":"1777_CR34","doi-asserted-by":"publisher","first-page":"e027049","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T et al (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9:e027049. https:\/\/doi.org\/10.1136\/bmjopen-2018-027049","journal-title":"BMJ Open"},{"key":"1777_CR35","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.clinthera.2019.05.001","volume":"41","author":"P Fardellone","year":"2019","unstructured":"Fardellone P, Lello S, Cano A et al (2019) Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review. Clin Ther 41:1576\u20131588. https:\/\/doi.org\/10.1016\/j.clinthera.2019.05.001","journal-title":"Clin Ther"},{"key":"1777_CR36","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/S0149-2918(99)80026-5","volume":"21","author":"KC Farmer","year":"1999","unstructured":"Farmer KC (1999) Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21:1074\u20131090. https:\/\/doi.org\/10.1016\/S0149-2918(99)80026-5 (discussion 1073)","journal-title":"Clin Ther"},{"key":"1777_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1179\/175709208X334614","volume":"1","author":"SR Leslie","year":"2008","unstructured":"Leslie SR, Gwadry-Sridhar F, Thiebaud P et al (2008) Calculating medication compliance, adherence and persistence in administrative pharmacy claims databases. Pharmaceutical Programming 1:13\u201319. https:\/\/doi.org\/10.1179\/175709208X334614","journal-title":"Pharmaceutical Programming"},{"key":"1777_CR38","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00198-013-2610-4","volume":"25","author":"K Ganda","year":"2014","unstructured":"Ganda K, Schaffer A, Pearson S et al (2014) Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporos Int 25:1345\u20131355. https:\/\/doi.org\/10.1007\/s00198-013-2610-4","journal-title":"Osteoporos Int"},{"key":"1777_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00774-008-0007-9","volume":"27","author":"A Giusti","year":"2009","unstructured":"Giusti A, Barone A, Razzano M et al (2009) Persistence with calcium and vitamin D in elderly patients after hip fracture. J Bone Miner Metab 27:95\u2013100. https:\/\/doi.org\/10.1007\/s00774-008-0007-9","journal-title":"J Bone Miner Metab"},{"key":"1777_CR40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1210\/jc.2003-030501","volume":"89","author":"JA Clowes","year":"2004","unstructured":"Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117\u20131123. https:\/\/doi.org\/10.1210\/jc.2003-030501","journal-title":"J Clin Endocrinol Metab"},{"key":"1777_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0022-3999(99)00058-6","volume":"47","author":"R Horne","year":"1999","unstructured":"Horne R (1999) Patients\u2019 beliefs about treatment: the hidden determinant of treatment outcome? J Psychosom Res 47:491\u2013495. https:\/\/doi.org\/10.1016\/s0022-3999(99)00058-6","journal-title":"J Psychosom Res"},{"key":"1777_CR42","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1007\/s00198-006-0166-2","volume":"17","author":"AJ Carr","year":"2006","unstructured":"Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638\u20131644. https:\/\/doi.org\/10.1007\/s00198-006-0166-2","journal-title":"Osteoporos Int"},{"key":"1777_CR43","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1023\/a:1018894827961","volume":"43","author":"CP Peter","year":"1998","unstructured":"Peter CP, Handt LK, Smith SM (1998) Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci 43:1998\u20132002. https:\/\/doi.org\/10.1023\/a:1018894827961","journal-title":"Dig Dis Sci"},{"key":"1777_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ijpharm.2012.04.073","volume":"432","author":"LA Hodges","year":"2012","unstructured":"Hodges LA, Connolly SM, Winter J et al (2012) Modulation of gastric pH by a buffered soluble effervescent formulation: a possible means of improving gastric tolerability of alendronate. Int J Pharm 432:57\u201362. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.04.073","journal-title":"Int J Pharm"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-020-01777-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-020-01777-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-020-01777-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T10:47:14Z","timestamp":1631184434000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-020-01777-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1777"],"URL":"https:\/\/doi.org\/10.1007\/s40520-020-01777-9","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AG has received consulting fees from bisphosphonate manufacturers: Abiogen, Internis Pharma, Labatec, Merck & Co, Chiesi, EffRx Pharmaceutical. GB has received consulting fees from bisphosphonate manufacturers: Abiogen, Novartis, Roche, Merck & Co, Chiesi. AB declares no conflict of interest. DMB has received consulting fees from EffRx Pharmaceutical and Asahi-Kasei.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study complies with the ethical standards of the Declaration of Helsinki and was approved by the local Ethical committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"All patients provided written informed consent to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}